{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:38:10Z","timestamp":1788482290670,"version":"build-2803163510"},"reference-count":65,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Bevacizumab is often used off-label in pediatric neuro-oncology, and evidence for indications of bevacizumab use in pediatric neuro-oncology is often fragmented. Therefore, this review aims to provide an organized summary of efficacy across different types of tumors, highlight outcomes, and link findings to the underlying biology. Gaps in the literature were also identified to guide future research. We narratively synthesized various pediatric studies, and the following tumor categories were identified for discussion: low-grade glioma, high-grade glioma, diffuse intrinsic pontine glioma, schwannoma, medulloblastoma, radiation necrosis, and cerebral edema. Key outcomes considered included overall survival, event-free survival, progression-free survival, vision and\/or hearing improvements, steroid use, quality of life, and toxicity. The greatest benefits were observed in cases such as recurrent medulloblastoma in combination with temozolomide and irinotecan, optic pathway glioma visual function, and diminished steroid use in radiation necrosis. Results were poorer in cases of newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. The medication was overall well tolerated, with adverse events like hypertension, proteinuria, and epistaxis often being manageable with surveillance. In consideration of the results, bevacizumab should be considered based on the tumor profile, and its outcome measured along functional endpoints, besides radiological evolution. Continued investigations into outcome measures, as well as combination with targeted treatments and optimizing therapy, will contribute to improving outcomes in this vulnerable population.<\/jats:p>","DOI":"10.3390\/curroncol32100573","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T07:29:38Z","timestamp":1760599778000},"page":"573","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bevacizumab in Pediatric Neuro-Oncology"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4314-9989","authenticated-orcid":false,"given":"Jacob","family":"Silverman","sequence":"first","affiliation":[{"name":"McGill Faculty of Medicine and Health Sciences, Montr\u00e9al,  QC H2V 4A9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayanthen","family":"Sathyakumar","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallie","family":"Coltin","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, CHU Sainte-Justine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H3C 3A7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Perreault","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Child Neurology, CHU Sainte-Justine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al,  QC H3C 3A7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Jabado","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGill University, Montreal, QC H4A 3J1, Canada"},{"name":"The Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-6539","authenticated-orcid":false,"given":"Eric","family":"Bouffet","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Hospital for Sick Children, Toronto, ON M5G 1E8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Renzi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology-Oncology, CHU de Qu\u00e9bec, Universit\u00e9 Laval, Qu\u00e9bec City, QC G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s00431-024-05540-4","article-title":"Advances in pediatric gliomas: From molecular characterization to personalized treatments","volume":"183","author":"Sathyakumar","year":"2024","journal-title":"Eur. J. Pediatr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ribatti, D., and Pezzella, F. (2021). Overview on the Different Patterns of Tumor Vascularization. Cells, 10.","DOI":"10.3390\/cells10030639"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Garcia-Romero, N., Palacin-Aliana, I., Madurga, R., Carrion-Navarro, J., Esteban-Rubio, S., Jimenez, B., Collazo, A., Perez-Rodriguez, F., Ortiz de Mendivil, A., and Fernandez-Carballal, C. (2020). Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. BMC Med., 18.","DOI":"10.1186\/s12916-020-01610-0"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdm510","article-title":"Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors","volume":"19","author":"Benesch","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100857","DOI":"10.1016\/j.neo.2022.100857","article-title":"Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era","volume":"36","author":"Manoharan","year":"2023","journal-title":"Neoplasia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pbc.21935","article-title":"Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan","volume":"52","author":"Packer","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/neuonc\/not154","article-title":"Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study","volume":"16","author":"Gururangan","year":"2014","journal-title":"Neuro Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Castelli, B., Fonte, C., Guidi, M., Tellini, M., Di Nicola, M., Iacono, A., Buccoliero, A.M., Greto, D., Genitori, L., and Sardi, I. (2023). Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: A case report. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1244628"},{"key":"ref_12","first-page":"359","article-title":"Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: A systematic review and meta-analysis of outcome rates","volume":"7","author":"Lu","year":"2020","journal-title":"Neurooncol. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/neuonc\/noac223","article-title":"A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes","volume":"25","author":"Green","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e27917","DOI":"10.1002\/pbc.27917","article-title":"Bevacizumab in treating the cystic components of pediatric low-grade gliomas: A report of four patients","volume":"66","author":"Levenbaum","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/jamaophthalmol.2013.5819","article-title":"Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab","volume":"132","author":"Avery","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/pbc.24297","article-title":"Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas","volume":"60","author":"Hwang","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100115","DOI":"10.1016\/j.ejcped.2023.100115","article-title":"Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center","volume":"2","author":"Lavarino","year":"2023","journal-title":"EJC Paediatr. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Calo, P., Pianton, N., Basle, A., Vasiljevic, A., Barritault, M., Beuriat, P.A., Faure-Conter, C., and Leblond, P. (2023). Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma. Cancers, 15.","DOI":"10.3390\/cancers15041036"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bennebroek, C.A.M., van Zwol, J., Porro, G.L., Oostenbrink, R., Dittrich, A.T.M., Groot, A.L.W., Pott, J.W., Janssen, E.J.M., Bauer, N.J., and van Genderen, M.M. (2022). Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study. Cancers, 14.","DOI":"10.3390\/cancers14246087"},{"key":"ref_20","unstructured":"Australian and New Zealand Children\u2019s Haematology Oncology Group, and The Hospital for Sick Children (2016). A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +\/\u2212 Bevacizumab for the Treatment of Chemotherapy-Na\u00efve Children With Unresectable or Progressive Low Grade Glioma (LGG), Hoffmann-La Roche."},{"key":"ref_21","unstructured":"Liu, A.P.Y.H., Eugene, I., Hansford, J.R., and Bouffet, E. (2024, January 17\u201320). Superiority of Bevacizumab and Vinblastine Combination Over Vinblastine Monotherapy in Unresectable or Progressive Pediatric Low-Grade Glioma: Results from an International, Phase II, Randomized-Controlled Trial. Proceedings of the SIOP Conference, Honolulu, HI, USA."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100210","DOI":"10.1016\/j.ejcped.2024.100210","article-title":"European-standard clinical practice recommendations for paediatric high-grade gliomas","volume":"5","author":"Szychot","year":"2024","journal-title":"EJC Paediatr. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"eabg4126","DOI":"10.1126\/sciadv.abg4126","article-title":"Epigenomic landscape and 3D genome structure in pediatric high-grade glioma","volume":"7","author":"Wang","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrclinonc.2012.87","article-title":"Paediatric and adult malignant glioma: Close relatives or distant cousins?","volume":"9","author":"Jones","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bennett, J., Erker, C., Lafay-Cousin, L., Ramaswamy, V., Hukin, J., Vanan, M.I., Cheng, S., Coltin, H., Fonseca, A., and Johnston, D. (2020). Canadian Pediatric Neuro-Oncology Standards of Practice. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.593192"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2009.26.8789","article-title":"Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study","volume":"28","author":"Gururangan","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1200\/JCO.2017.76.0611","article-title":"Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma","volume":"36","author":"Grill","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ccell.2018.04.004","article-title":"Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial","volume":"33","author":"Mackay","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_29","first-page":"vdae035","article-title":"Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV\/TMZ in pediatric high-grade glioma: A Children\u2019s Oncology Group Study","volume":"6","author":"Lulla","year":"2024","journal-title":"Neurooncol. Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/neuonc\/noq033","article-title":"Bevacizumab in recurrent high-grade pediatric gliomas","volume":"12","author":"Narayana","year":"2010","journal-title":"Neuro Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s11547-021-01381-5","article-title":"Bevacizumab in recurrent high-grade glioma: A single institution retrospective analysis on 92 patients","volume":"126","author":"Detti","year":"2021","journal-title":"Radiol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Fu, M., Zhou, Z., Huang, X., Chen, Z., Zhang, L., Zhang, J., Hua, W., and Mao, Y. (2023). Use of Bevacizumab in recurrent glioblastoma: A scoping review and evidence map. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11043-6"},{"key":"ref_33","first-page":"145","article-title":"Management of high-grade gliomas in the pediatric patient: Past, present, and future","volume":"1","author":"Vanan","year":"2014","journal-title":"Neurooncol. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s11060-020-03558-w","article-title":"Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: The Seattle Children\u2019s Hospital experience","volume":"148","author":"Crotty","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.adro.2019.03.009","article-title":"Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review","volume":"4","author":"Gallitto","year":"2019","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11060-021-03763-1","article-title":"A phase I\/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma","volume":"153","author":"Jansen","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_37","first-page":"vdac100","article-title":"Does a Bevacizumab-based regime have a role in the treatment of children with diffuse intrinsic pontine glioma? A systematic review","volume":"4","author":"Evans","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103148","DOI":"10.1016\/j.amjoto.2021.103148","article-title":"Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis","volume":"42","author":"Shi","year":"2021","journal-title":"Am. J. Otolaryngol."},{"key":"ref_39","first-page":"vdad099","article-title":"A systematic review of targeted therapy for vestibular schwannoma in patients with NF2-related schwannomatosis","volume":"5","author":"Chiranth","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Tops, A.L., Schopman, J.E., Koot, R.W., Gelderblom, H., Putri, N.A., Rahmi, L.N.A., Jansen, J.C., and Hensen, E.F. (2025). Efficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review. Cancers, 17.","DOI":"10.3390\/cancers17030519"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e28228","DOI":"10.1002\/pbc.28228","article-title":"Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence","volume":"67","author":"Renzi","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/neuonc\/nos213","article-title":"Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study","volume":"14","author":"Gururangan","year":"2012","journal-title":"Neuro Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/pbc.22868","article-title":"Bevacizumab and irinotecan in the treatment of children with recurrent\/refractory medulloblastoma","volume":"56","author":"Aguilera","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e29031","DOI":"10.1002\/pbc.29031","article-title":"Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial","volume":"68","author":"Levy","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_45","first-page":"489","article-title":"Children with medulloblastoma treated with modified ACNS0821 temozolomide, irinotecan, and bevacizumab: The Seattle Children\u2019s Hospital experience","volume":"12","author":"Ronsley","year":"2025","journal-title":"Neurooncol. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1001\/jamaoncol.2023.4437","article-title":"Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial","volume":"9","author":"Peyrl","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_47","first-page":"409","article-title":"Bevacizumab for pediatric radiation necrosis","volume":"7","author":"Baroni","year":"2020","journal-title":"Neurooncol. Pract."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijrobp.2023.07.015","article-title":"A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and International Stereotactic Radiosurgery Society Recommendations","volume":"118","author":"Vellayappan","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Barone, A., and Rubin, J.B. (2013). Opportunities and challenges for successful use of bevacizumab in pediatrics. Front. Oncol., 3.","DOI":"10.3389\/fonc.2013.00092"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.ijrobp.2008.12.032","article-title":"Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas","volume":"75","author":"Liu","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11060-016-2219-5","article-title":"Treatment of pediatric cerebral radiation necrosis: A systematic review","volume":"130","author":"Drezner","year":"2016","journal-title":"J. Neurooncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1586\/14737140.2013.852473","article-title":"Tumor-associated edema in brain cancer patients: Pathogenesis and management","volume":"13","author":"Roth","year":"2013","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_53","first-page":"261","article-title":"Brain edema in neurooncology: Radiological assessment and management","volume":"27","author":"Wick","year":"2004","journal-title":"Onkologie"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1634\/theoncologist.2010-0105","article-title":"Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study","volume":"15","author":"Vredenburgh","year":"2010","journal-title":"Oncologist"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrclinonc.2009.14","article-title":"VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer","volume":"6","author":"Gerstner","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/MPH.0000000000002792","article-title":"Bevacizumab in the Treatment of Refractory Brain Edema in High-grade Glioma","volume":"46","author":"Alsahlawi","year":"2024","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Bai, X., Feng, M., Ma, W., and Wang, S. (2025). Predicting the efficacy of bevacizumab on peritumoral edema based on imaging features and machine learning. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-00758-0"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00381-022-05479-7","article-title":"A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent\/refractory central nervous system tumors","volume":"38","author":"Metts","year":"2022","journal-title":"Childs Nerv. Syst."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1002\/cncr.28343","article-title":"Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): A Pediatric Brain Tumor Consortium Study (PBTC-022)","volume":"119","author":"Fangusaro","year":"2013","journal-title":"Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1158\/1078-0432.CCR-13-2364","article-title":"Population pharmacokinetics of bevacizumab in children with osteosarcoma: Implications for dosing","volume":"20","author":"Turner","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Ollauri-Ibanez, C., and Astigarraga, I. (2021). Use of Antiangiogenic Therapies in Pediatric Solid Tumors. Cancers, 13.","DOI":"10.3390\/cancers13020253"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3892\/mco.2017.1237","article-title":"Ovarian function following targeted anti-angiogenic therapy with bevacizumab","volume":"6","author":"Imai","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"iii411","DOI":"10.1093\/neuonc\/noaa222.578","article-title":"MODL-01. Safety in Concomitant Use of Mek and Braf Inhibitors with Bevacizumab","volume":"22","author":"Winzent","year":"2020","journal-title":"Neuro-Oncol."},{"key":"ref_64","first-page":"vdad118","article-title":"Evolution and implementation of radiographic response criteria in neuro-oncology","volume":"5","author":"Ramakrishnan","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"CNS28","DOI":"10.2217\/cns-2018-0007","article-title":"Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice","volume":"8","author":"Chukwueke","year":"2019","journal-title":"CNS Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/10\/573\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T08:26:48Z","timestamp":1760689608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/10\/573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":65,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["curroncol32100573"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32100573","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}